Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

Condition(s) studied

Investigational drug(s) / intervention(s)

Micro-biopsies: Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.

Study summary

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.

Eligibility

Primary outcome measure(s)

• Number of RNA transcripts between lymphoedema limb and healthy limb — Day 1
  The gene expression profile of primary and secondary lymphedema will be determined by high-throughput RNA sequencing (RNAseq) or next-generation sequencing (NGS). It is a molecular methodology that allows the rapid sequencing of thousands to millions of RNA molecules simultaneously, determining the unique and specific order of nucleic acid bases. It is a random sequencing of the whole transcriptome which is used to identify and quantify the RNA resulting from the transcription of the genome at a given time.

Trial sites (1)

More University Hospital, Toulouse trials in France

Other trials for the same condition